Investigation of the relevance of increased FVIII activity as a risk factor in venous and arterial thrombosis

Investigation of the relevance of increased FVIII activity as a risk factor in venous and arterial thrombosis - FVIII_Thromb

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00036844

Enrollment

200

Registered

2025-08-18

Start date

2025-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I80

Interventions

Group 1: Patients with thrombosis event, thrombophilia screening and at least two measurement of FVIII acitivity = 180 %

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - thrombosis event - at least two measurements of FVIII activity =180% (IU/dL)

Exclusion criteria

Exclusion criteria: no thrombosis event, FVIII activity < 180 % or FVIII activity = 180 %, but measurement: -< 4 weeks past thrombosis event - during pregnancy or postpartum - sepsis - COVID-19 diagnosis - liver cirrhosis

Design outcomes

Primary

Measure	Time frame
- FVIII activity - VW antigen, VW activity - thrombophilia screening: aPTT, fibrinogen, protein C activity, lupus anticoagulans, Protein S, Anti-Cardiolipin-antibody, antithrombin, Beta-2-glykoprotein-antibody, Faktor V-Leiden-Mutation, Prothrombin-Mutation, Akut-Phase Marker	—

Secondary

Measure	Time frame
- sex, age at thrombosis event, BMI - anamnesis/family anamnesis of thrombosis/abortion - venous/arterial thrombosis: location/severity - risk factors: permanment, transient - Treatment (heparin, DOACs, NSAIDs) -outcome (recanalization, recurrences, post-thrombotic syndrome/residues) - duration of primary and secondary prophylaxis - known coagulation disorders - co-morbidities/co-medication - mortality	—

Measure

Time frame

- sex, age at thrombosis event, BMI - anamnesis/family anamnesis of thrombosis/abortion - venous/arterial thrombosis: location/severity - risk factors: permanment, transient - Treatment (heparin, DOACs, NSAIDs) -outcome (recanalization, recurrences, post-thrombotic syndrome/residues) - duration of primary and secondary prophylaxis - known coagulation disorders - co-morbidities/co-medication - mortality

—

Countries

Germany

Contacts

Public ContactWolfgang Miesbach

Universitätsklinikum Frankfurt, Hämophiliezentrum/Hämostaseologie

Wolfgang.miesbach@unimedizin-ffm.de+496963015051

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026